Evaluating New Antiviral and Antibiotic Drug Candidates

| February 16, 2017

article image
The development of anti-infective treatments to combat illnesses caused by viral and microbial agents has witnessed many unique advances, most notably in the fights against bacterial infections, hepatitis and HIV.

Spotlight

Ferrosan Medical Devices A/S

Ferrosan Medical Devices provides a range of innovative medical devices. Our focus is centered on haemostasis during surgery, regional anaesthesia and biopsy. Ferrosan Medical Devices consists of two entities: Biomaterials & Electromechanics. Biomaterials develops and manufactures advanced topical haemostatic products to control bleeding in surgery. The products are marketed in more than 100 countries around the globe via Ethicon Biosurgery, a Johnson & Johnson Company. In addition, selected countries and segments are served by Takeda, Sanofi-Aventis and Elanco Animal Health.

OTHER ARTICLES

Comparing HydroxyChloroquine Trials

Article | April 1, 2020

One minor side effect of the pandemic is that perhaps more people will learn about what drug research and clinical trials can really be like. Today’s example: we have a clinical trial of hydroxychloroquine from Wuhan that has just published on a preprint server. What’s good is that this one is blinded, randomized, and controlled (like the earlier hydroxychloroquine which one I blogged about here from Zhejiang University, so we can actually talk about it rather than just spend all our time wondering what the heck is going on.

Read More

What to Watch in 2020: Non-Specialty Drugs

Article | April 1, 2020

Pharmaceutical manufacturers are constantly working to develop new and improved medications. Join us as we explore the non-specialty drugs you should be watching in 2020. If you missed last week’s article about the most important upcoming specialty drugs, be sure to check it out here. Approximately 40 new medications are approved by the Food and Drug Administration (FDA) every year.1 (Please note: If you’re curious about what it takes to develop a drug and bring it to market, check out our previous article). Why should you care about these new medications? Because they can affect both your organization’s pharmacy spend and your members’ cost share. For non-specialty drugs, we will focus on medications that may come to market this year, including ones that are currently being reviewed by the FDA, or that are in the last clinical trial (Phase III) stage.

Read More

How Pharma Companies Can Scale Up Their Knowledge Discovery with Semantic Similarity Search

Article | April 1, 2020

Pharma has deep roots in human history with centuries of folk pharmaceutical knowledge offering a hit-and-miss range of natural remedies. But the industry as we know it today actually emerged in the second half of the 19th century when the world’s first factory for the sole production of medicines was found. By the late 19th and early 20th century, some chemical companies had already begun using research labs to explore the medical applications for their products. Fast forward to today and the pharmaceutical sector is a global trillion-dollar industry. However, to ensure the safety and efficacy of drugs, the process of drug discovery and development is under extensive scrutiny and control on both national and global levels.

Read More

What do you have to lose taking hydroxychloroquine for coronavirus? Potentially your life

Article | April 1, 2020

The president and some of his close advisors — desperate for a COVID-19 cure — are asking “What do you have to lose?” by taking hydroxychloroquine (HCQ), a strong medication never adequately tested for efficacy or safety in COVID-19 patients. The correct answer to the president’s question, which he doesn’t seem to want to hear, is that we have our lives to lose. The president acknowledges “I’m not a doctor” but this raises the question “What do doctors know about the drug recommended by the president? Most doctors are aware that HCQ can be effective for patients with malaria, arthritis or lupus. If they were to follow the president’s suggestion and prescribe it for COVID-19 patients, they would also like to know that it will benefit some of those patients, at least.

Read More

Spotlight

Ferrosan Medical Devices A/S

Ferrosan Medical Devices provides a range of innovative medical devices. Our focus is centered on haemostasis during surgery, regional anaesthesia and biopsy. Ferrosan Medical Devices consists of two entities: Biomaterials & Electromechanics. Biomaterials develops and manufactures advanced topical haemostatic products to control bleeding in surgery. The products are marketed in more than 100 countries around the globe via Ethicon Biosurgery, a Johnson & Johnson Company. In addition, selected countries and segments are served by Takeda, Sanofi-Aventis and Elanco Animal Health.

Events